Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial - Younes, A; Santoro, A; Shipp, M (The Lancet Oncology, 2016)
. doi:10.1016/S1470-2045(16)30167-X